thyroid eye disease

Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials

Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of commercializing the drug

James Waldron Apr 2, 2026 7:27am

Viridian’s Tepezza rival scores ph. 3 win, but investors unsure

Mar 30, 2026 10:11am

Yarrow blooms with $1.37B autoimmune thyroid disease deal

Dec 16, 2025 11:00am

Three blocks displaying from left to right a person a handshake and another person

Kissei pays Viridian $70M to challenge Amgen for Japanese market

Jul 30, 2025 4:50am

MA strategy deal block push come together form

Acelyrin to be absorbed into Alumis in all-stock merger

Feb 7, 2025 5:35am

Sling's oral Tepezza rival hits goal in thyroid eye disease

Jan 14, 2025 8:16am